首页AYJ • FRA
add
瓦尔内瓦
市场资讯
财务信息
损益表
收入
净收入
(EUR) | 2025年3月info | 年同比变化 |
---|---|---|
收入 | 4923.20万 | 50.31% |
经营支出 | 1719.70万 | 124.31% |
净收入 | -923.20万 | -115.67% |
净利润率 | -18.75 | -110.42% |
每股收益 | -0.14 | -115.41% |
息税折旧摊销前利润 | -228.48万 | -103.21% |
有效税率 | -19.00% | — |
资产负债表
总资产
负债总额
(EUR) | 2025年3月info | 年同比变化 |
---|---|---|
现金及短期投资 | 1.53亿 | -13.39% |
总资产 | 4.82亿 | -4.09% |
负债总额 | 3.07亿 | -2.11% |
权益总额 | 1.75亿 | — |
发行在外的股份 | 1.54亿 | — |
市净率 | 2.42 | — |
资产回报率 | -3.03% | — |
资本回报率 | -3.80% | — |
现金流
现金净变动
(EUR) | 2025年3月info | 年同比变化 |
---|---|---|
净收入 | -923.20万 | -115.67% |
来自运营的现金 | -814.80万 | 71.34% |
投资现金 | -96.10万 | -101.11% |
融资现金 | -558.20万 | 25.14% |
现金净变动 | -1528.10万 | -130.22% |
自由现金流 | -1967.55万 | -198.73% |
简介
Valneva SE is a speciality vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company current market three proprietary travel vaccines.
Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
CEO
成立时间
2013
员工数量
713